Plus Therapeutics Inc (PSTV)

03:09 AM

What drives Plus Therapeutics Inc. stock priceExplosive portfolio gains - Autocar Professional

03:09 AM

03:06 AM

Is Plus Therapeutics Inc. a good long term investmentExceptional trading results - Autocar Professional

03:06 AM

08:02 AM

Plus Therapeutics (PSTV) Receives $1.6M Advance from CPRIT Grant | PSTV Stock News - GuruFocus

08:02 AM

08:02 AM

Plus Therapeutics (PSTV) Secures $1.6 Million Advance from Texas Institute - GuruFocus

08:02 AM

07:57 AM

Plus Therapeutics: Leveraging Non-Dilutive Funding to Accelerate CNS Cancer Innovation - AInvest

07:57 AM

07:46 AM

Plus Therapeutics Announces $1.6 Million Advance Payment from CP - GuruFocus

07:46 AM

07:43 AM

Plus Therapeutics, Inc. Secures $1.6 Million Advance Payment from CPRIT to Support CNS Cancer Research and Development - Quiver Quantitative

07:43 AM

07:42 AM

Plus Therapeutics receives $1.6 million advance from CPRIT grant - Investing.com India

07:42 AM

07:31 AM

Plus Therapeutics Announces $1.6 Million Advance Payment from CPRIT - GlobeNewswire

07:31 AM

07:20 AM

Plus Therapeutics Inc. Stock Analysis and ForecastBreakthrough stock performance - jammulinksnews.com

07:20 AM

02:56 AM

What analysts say about Plus Therapeutics Inc. stockSignificant capital appreciation - Autocar Professional

02:56 AM

Jul 17, 2025

Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics - Yahoo

Jul 17, 2025

Jul 16, 2025

Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates - MSN

Jul 16, 2025

Jul 15, 2025

Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases | PSTV Stock News - GuruFocus

Jul 15, 2025

Jul 15, 2025

Plus Therapeutics Announces Clinical Trial Presentation and Educational Symposium at 2025 SNO/ASCO CNS Metastases Conference - Nasdaq

Jul 15, 2025

Jul 15, 2025

Plus Therapeutics Presents ReSPECT-LM Clinical Trial - GlobeNewswire

Jul 15, 2025

Jul 15, 2025

Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases - TradingView

Jul 15, 2025

Jul 11, 2025

Plus Therapeutics Advances Pediatric Brain Tumor Treatment with New Clinical Study - TipRanks

Jul 11, 2025

Jul 11, 2025

Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference - GlobeNewswire

Jul 11, 2025

Jul 10, 2025

Plus Therapeutics Announces Two CNSide Presentations at the Upco - GuruFocus

Jul 10, 2025

Jul 10, 2025

Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference | PSTV Stock News - GuruFocus

Jul 10, 2025

Jul 10, 2025

Plus Therapeutics' CNSide Showcases Innovative CSF Assay Data at SNO/ASCO CNS Metastases Conference 2025 - Nasdaq

Jul 10, 2025

Jul 10, 2025

Revolutionary CNS Cancer Detection: Plus Therapeutics Unveils Game-Changing Clinical Data at Major Conference - Stock Titan

Jul 10, 2025

Jul 09, 2025

Plus Therapeutics Soars 10.51% on Promising Clinical Trial Results - AInvest

Jul 09, 2025

Jul 09, 2025

Plus Therapeutics begins treatment in REYOBIQ dose optimization trial By Investing.com - Investing.com South Africa

Jul 09, 2025

Jul 08, 2025

Plus Therapeutics Announces Initial Patients Successfully - GlobeNewswire

Jul 08, 2025

Jul 08, 2025

Plus Therapeutics begins treatment in REYOBIQ dose optimization trial - Investing.com

Jul 08, 2025

Jul 08, 2025

Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases | PSTV Stock News - GuruFocus

Jul 08, 2025

Jul 08, 2025

Plus Therapeutics announces initial patients successfully treated in ReSPECT-LM dose optimization trial for Reyobiq™ in leptomeningeal metastases - MarketScreener

Jul 08, 2025

Jul 08, 2025

Plus Therapeutics Initiates ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases Treatment - Nasdaq

Jul 08, 2025

Jul 08, 2025

Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases - The Manila Times

Jul 08, 2025

Jul 08, 2025

Breakthrough Brain Cancer Drug REYOBIQ Achieves 80% Tumor Reduction in Phase 1 Trial, Advances to Next Stage - Stock Titan

Jul 08, 2025

Jul 07, 2025

Plus Therapeutics shares fall 3.72% premarket after FDA clearance of Reyobiq for childhood brain cancer. - AInvest

Jul 07, 2025

Jul 03, 2025

Plus Therapeutics, Inc. shares fall 1.63% premarket after Novartis' Cosentyx fails in Phase III GCAptAIN study. - AInvest

Jul 03, 2025

Jul 01, 2025

Stock under $1with a very strong catalyst to buy and hold for a minimum of three years - AInvest

Jul 01, 2025

Jun 30, 2025

Plus Therapeutics Advances Brain Cancer Treatment: FDA Green Light and $17.6M Boost for Critical Trial - Stock Titan

Jun 30, 2025

Jun 29, 2025

Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM - GuruFocus

Jun 29, 2025

Jun 29, 2025

PSTV SEC FilingsPlus Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Jun 29, 2025

Jun 27, 2025

H.C. Wainwright Adjusts Price Target for Plus Therapeutics (PSTV) | PSTV Stock News - GuruFocus

Jun 27, 2025

Jun 26, 2025

Plus Therapeutics (PSTV) to Update on CNSide Diagnostics Busines - GuruFocus

Jun 26, 2025

Jun 25, 2025

Plus Therapeutics (PSTV) Shares Surge After FDA Trial Clearance - GuruFocus

Jun 25, 2025

Jun 25, 2025

PSTV Stock Update: D. Boral Capital Maintains Hold Rating for Plus Therapeutics | PSTV Stock News - GuruFocus

Jun 25, 2025

Jun 24, 2025

Plus Therapeutics Announces Restructuring Of Its Equity Financing - Nasdaq

Jun 24, 2025

Jun 20, 2025

Plus Therapeutics drops 5%, files prospectus for 17M share secondary offering - MSN

Jun 20, 2025

Jun 19, 2025

Plus (PSTV) Upgraded to Buy: Here's Why - Nasdaq

Jun 19, 2025

Jun 18, 2025

Dow Surges 150 Points; Korn Ferry Earnings Top Views - Benzinga

Jun 18, 2025

Jun 18, 2025

Plus Therapeutics (PSTV) Sees Stock Dip Amid New Share Sale Fili - GuruFocus

Jun 18, 2025